新浪登录
腾讯登录CHL收购风险评估工具 占领美国心血管病预防市场
| 导读 | Cleveland HeartLab公司（CHL）正式宣布完成了对心血管疾病风险评估工具MIRISK的购买，交易涉及金额尚未披露。 |
Cleveland HeartLab公司（CHL）正式宣布完成了对心血管疾病风险评估工具MIRISK的购买，交易涉及金额尚未披露。
MIRISK测试由斯坦福大学医学院的研究人员开发，使用专有的算法来分析与血液脆弱斑块发展有关的关键蛋白。该评估工具的前所有者Aviir公司在2014年早些时候陷入了面临破产的窘境。通过对MIRISK的使用，CHL表示，心血管病医疗公司可以综合其他因素对病人五年内心脏病发病风险作出有效评估。CHL的收购包括测试知识产权、版权和品牌资产。
CHL心血管病研究所研究主管和首席营销官Marc Penn在声明中表示：“目前已经有研究证实了CHL持自主知识产权的心血管疾病炎症测试技术的有效性，而MIRISK正完美地补充了我们公司的心血管疾病预测技术。我们专利与MIRISK的结合将是心血管疾病风险评估领域的飞跃性进步，能帮助病人更加有效地预防心脏病和中风。”
CHL表示，援引美国疾病控制和预防中心的统计数据，美国每年大约有60万美国人死于心血管疾病。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理。如需转载，请联系 info@360zhyx.com 。
转化医学网推荐的新闻阅读：
Cleveland HeartLab announced today it has acquired the MIRISK cardiovascular disease risk assessment tool for an undisclosed amount.Aviir, which entered into bankruptcy in early 2014, previously owned MIRISK. The test was developed by researchers at Stanford University School of Medicine and uses a proprietary algorithm to analyze key proteins in blood associated with the development of vulnerable plaque. The use of MIRISK, when factoring in other risk factors, can determine an individual's risk of having a heart attack within a five-year period, CHL said.
CHL's acquisition includes intellectual property around the test, copyrights, and brand assets.
Studies have validated CHL's own proprietary cardiovascular disease inflammation test, and MIRISK "complements our arsenal of prognostic testing," Marc Penn, director of research at Summa Cardiovascular Institute and CMO at CHL, said in a statement. "Together, these two represent a significant leap forward in the advancement of [cardiovascular disease] risk assessment, and, ultimately, heart attack and stroke prevention."
About 600,000 Americans die each year from cardiovascular disease, CHL said, citing statistics from the US Centers for Disease Control and Prevention.
还没有人评论，赶快抢个沙发